Developing strategic priorities in osteoarthritis research: Proceedings and recommendations arising from the 2017 Australian Osteoarthritis Summit
- PMID: 30760253
- PMCID: PMC6375218
- DOI: 10.1186/s12891-019-2455-x
Developing strategic priorities in osteoarthritis research: Proceedings and recommendations arising from the 2017 Australian Osteoarthritis Summit
Abstract
Background: There is a pressing need to enhance osteoarthritis (OA) research to find ways of alleviating its enormous individual and societal impact due to the high prevalence, associated disability, and extensive costs.
Methods: Potential research priorities and initial rankings were pre-identified via surveys and the 1000Minds process by OA consumers and the research community. The OA Summit was held to decide key research priorities that match the strengths and expertise of the Australian OA research community and align with the needs of consumers. Facilitated breakout sessions were conducted to identify initiatives and strategies to advance OA research into agreed priority areas, and foster collaboration in OA research by forming research networks.
Results: From the pre-Summit activities, the three research priority areas identified were: treatment adherence and behaviour change, disease modification, and prevention of OA. Eighty-five Australian and international leading OA experts participated in the Summit, including specialists, allied health practitioners, researchers from all states of Australia representing both universities and medical research institutes; representatives from Arthritis Australia, health insurers; and persons living with OA. Through the presentations and discussions during the Summit, there was a broad consensus on the OA research priorities across stakeholders and how these can be supported across government, industry, service providers and consumers.
Conclusion: The Australian OA Summit brought consumers, experts and opinion leaders together to identify OA research priorities, to enhance current research efforts by fostering collaboration that offer the greatest potential for alleviating the disease burden.
Keywords: Osteoarthritis; Research priorities.
Conflict of interest statement
Ethics approval and consent to participate
Ethics approval was granted by the School of Health Sciences Human Ethics Advisory Group, University of Melbourne (HREC #1648500.1). Written informed consent was obtained from all participants before entering the study.
Consent for publication
Not applicable.
Competing interests
DJH provides consulting advice to Tissuegene, Merck Serono and TLCBio. CBL receives funding from Taisho Pharmaceutical, Concentric Analgesics, and Inter-K Peptide Therapeutics to conduct pre-clinical research in OA, through contract agreements managed by the University of Sydney.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
-
- Knox SA, Harrison CM, Britt HC, Henderson JV. Estimating prevalence of common chronic morbidities in Australia. MedJAust. 2008;189(2):66–70. - PubMed
-
- Prevalence of disabilities and associated health conditions among adults--United States, 1999. [erratum appears in MMWR Morb Mortal Wkly Rep 2001 Mar 2;50(8):149.]. MMWR - Morbidity & Mortality Weekly Report. 2001;50(7):120–5. - PubMed
-
- Painful realities: The economic impact of arthritis in Australia 2007. Available from: http://www.arthritisaustralia.com.au/images/stories/documents/reports/20.... Accessed 11 Feb 2019.
-
- The Impact of Arthritis in Canada: Today and Over the Next 30 Years was prepared by the Arthritis. Alliance of Canada. 2011. Available from: http://www.arthritisalliance.ca/images/PDF/eng/Initiatives/20111022_2200.... Accessed 11 Feb 2019.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical